Last reviewed · How we verify
Third generation cephalosporins
Third-generation cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.
Third-generation cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. Used for Bacterial infections caused by susceptible gram-positive and gram-negative organisms, Respiratory tract infections, Urinary tract infections.
At a glance
| Generic name | Third generation cephalosporins |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Beta-lactam antibiotic (cephalosporin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These beta-lactam antibiotics penetrate the bacterial cell wall and covalently bind to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands essential for cell wall integrity. This leads to cell wall weakening, osmotic instability, and bacterial cell lysis. Third-generation cephalosporins have enhanced activity against gram-negative organisms and improved beta-lactamase stability compared to earlier generations.
Approved indications
- Bacterial infections caused by susceptible gram-positive and gram-negative organisms
- Respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Meningitis
- Sepsis
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Hypersensitivity reactions
- Pseudomembranous colitis
- Elevated liver enzymes
Key clinical trials
- Streptococcus Pneumoniae Nasopharyngeal Carriage (NA)
- The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial (NA)
- Study on the Effects and Mechanisms of Modified Ma Xing Shi Gan Decoction in Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease (NA)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins (PHASE3)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Transurethral Focal Laser Ablation Versus Transurethral Prostatectomy For Management Of Benign Prostatic Obstruction (NA)
- Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: